Substance used to diagnose, cure, treat, or prevent disease
POPULARITY
Categories
189 episodes with drug administration
133 episodes with drug administration
157 episodes with drug administration
115 episodes with drug administration
197 episodes with drug administration
104 episodes with drug administration
71 episodes with drug administration
86 episodes with drug administration
72 episodes with drug administration
43 episodes with drug administration
101 episodes with drug administration
78 episodes with drug administration
89 episodes with drug administration
59 episodes with drug administration
37 episodes with drug administration
99 episodes with drug administration
57 episodes with drug administration
45 episodes with drug administration
80 episodes with drug administration
36 episodes with drug administration
28 episodes with drug administration
17 episodes with drug administration
25 episodes with drug administration
68 episodes with drug administration
52 episodes with drug administration
19 episodes with drug administration
86 episodes with drug administration
20 episodes with drug administration
17 episodes with drug administration
20 episodes with drug administration
18 episodes with drug administration
22 episodes with drug administration
30 episodes with drug administration
14 episodes with drug administration
13 episodes with drug administration
32 episodes with drug administration
27 episodes with drug administration
17 episodes with drug administration
24 episodes with drug administration
12 episodes with drug administration
45 episodes with drug administration
33 episodes with drug administration
19 episodes with drug administration
18 episodes with drug administration
39 episodes with drug administration
15 episodes with drug administration
13 episodes with drug administration
19 episodes with drug administration
36 episodes with drug administration
26 episodes with drug administration
35 episodes with drug administration
9 episodes with drug administration
6 episodes with drug administration
12 episodes with drug administration
Guest Full Name: Dr. R. Stacy Lindborg, PhDGuest Title: President, Chief Executive Officer, and Board DirectorCompany: IMUNONTicker: IMNNWebsite: https://imunon.com/Guest Bio:Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of IMUNON in May 2024. Dr. Lindborg has served on IMUNON's Board of Directors since June 2021. She has nearly 30 years of experience in the pharmaceutical and biotech industries, with a particular focus on R&D, regulatory affairs, executive management, and strategy development. She has designed, hired, and led global teams, guiding long-term visions for growth through analytics and stimulating innovative development platforms to increase productivity.Prior to joining IMUNON, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics, where she remains a member of the company's Board of Directors. At BrainStorm, she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She frequently interacted with investors and analysts, represented the company in the scientific community and with the media, and played an active role in discussions with potential business partners.Dr. Lindborg previously was Vice President and Head of Global Analytics and Data Sciences, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company, where, over the course of 16 years, she assumed positions of increasing responsibility, including Head of R&D strategy.Dr. Lindborg received an MA and PhD in statistics, and a BA in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.Company Bio:IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of diseases. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.IMUNON's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 is the first therapy to achieve a clinically effective response in advanced (stage IIIC/IV) ovarian cancer including benefits in both progression-free survival (PFS) and overall survival (OS) in a first-line treatment setting when used with standard of care chemotherapy. IMUNON has completed multiple clinical trials evaluating the potential of IMNN-001, including one Phase 2 clinical trial (OVATION 2), and is currently conducting a Phase 3 clinical trial (OVATION 3). The first patient was dosed in the Phase 3 study in the third quarter of 2025. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as IL-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
It's been a busy week at the Food and Drug Administration, with a political appointee overruling agency scientists to reject an application for a new flu vaccine, a decision that's reverberating through the drug industry. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Lizzy Lawrence of Stat, and Jackie Fortiér of KFF Health News join KFF Health News' Julie Rovner. Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too: Julie Rovner: ProPublica's “The Children of Dilley,” by Mica Rosenberg. Alice Miranda Ollstein: Politico's “Why Washington's All-In on Smart Rings,” by Amanda Chu. Lizzy Lawrence: KFF Health News' “US Cancer Institute Studying Ivermectin's ‘Ability To Kill Cancer Cells,'” by Rachana Pradhan. Jackie Fortiér: Stat's “The New Childhood Vaccine Guidelines Have a Paid Leave Problem,” by Ariana Hendrix.
It's Thursday, February 12th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com. I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Olympics can prompt prayer among Christian viewers (Audio of Olympic theme song) Over 3,500 athletes from 93 countries are competing at the 2026 Winter Olympics Games in Milan, Italy this month. Fourteen of these countries are on the Open Doors' World Watch List of the most oppressive places to be a Christian. Those countries include Eritrea, Nigeria, Pakistan, Iran, India, and China. Open Doors has a message for Christian viewers of the Olympics. They said, “Use the Olympics in a potentially surprising way: to pray. … Take a moment to think about the situation of your brothers and sisters in that country and pray for it.” You can reference the organization's prayer guide for each country through a link in our transcript today at TheWorldview.com. Ephesians 6:18 says, “Pray at all times in the Spirit with every prayer and request, and stay alert with all perseverance and intercession for all the saints.” Canadian gunman killed 10 people at school Tragically, a transgender shooter opened fire at a Canadian school on Tuesday, reports LifeSiteNews.com. Jesse Strang, a 17-year-old male pretending to be a female while wearing a dress, reportedly killed 10 people including himself. He also injured 25 people. It's Canada's deadliest school shooting in decades. The shooting took place at Tumbler Ridge Secondary School in northeastern British Columbia which has fewer than 200 students enrolled in Grades 7 through 12. Chris Elston, a Canadian pro-family activist, said, “He was a young man who needed serious help for his mental health. Instead, his delusion was affirmed, and the result is murdered innocent children.” Later, Elston added, “Someone needed to tell this kid the truth and help him to be happy as a man, but it's illegal to do so. It's a criminal offense of conversion therapy. So, he never got help and he got worse. Murdered children paid the price for our politicians' stupidity and cowardice. Not even our police can call him a man. A cult has taken over our society. “ Please pray for the families suffering through this unimaginable loss. YouVersion Bible engagement up dramatically in Latin America Online Bible platforms are seeing unprecedented engagement in Latin America so far this year. This trend marks a year since the YouVersion Bible platform established a regional office in Mexico City. On January 1, nearly two million people subscribed to Bible reading plans. And the app saw over 22.2 million active users on the first Sunday of the year. This marks a 20% growth from last year. Countries with record levels of engagement include Mexico, Colombia, Argentina, and El Salvador. Only 31% o Protestants read Bible daily In the United States, new analysis from Lifeway Research found most Protestant churchgoers don't read the Bible on a daily basis. Seventeen percent of churchgoers read the Bible at least monthly. Fourteen percent read weekly. Thirty percent read a few times a week. And only 31% read the Bible daily. However, the percentage of churchgoers who read the Bible daily or at least a few times a week is now 61%. That's up from 36% in 2007. Romans 12:2 reminds us, “Do not be conformed to this world, but be transformed by the renewing of your mind, that you may prove what is that good and acceptable and perfect will of God.” GOP to FDA: Abortion Kill Pill is hurting women U.S. Senate Republicans criticized the Food and Drug Administration on Tuesday after a closed-door briefing on the abortion kill pill. The FDA is supposed to be conducting a safety review of mifepristone, one of the drugs used in chemical abortions. Republicans are accusing the agency of dragging its feet on the study. Listen to comments from Republican Senator Josh Hawley of Missouri in an interview on Washington Watch with Tony Perkins of the Family Research Council. HAWLEY: “Tony. I just think, at this point, this study, it's vital. It should be done. I don't have any confidence that the FDA is actually going to do it. And, in the meantime, abortions in this country are increasing. There are more abortions now than when Roe was the law of the land. And that's because of this chemical abortion.” U.S. homicides down 20% The Major Cities Chiefs Association released its latest report on violent crime in the U.S. The report collects data from 67 of America's biggest police departments. Compared to 2024, reported homicides were down nearly 20% last year. And reported violent crimes are falling after a surge of reports during the COVID-era shutdowns. 130,000 new American jobs The United States added 130,000 jobs in January, according to the Bureau of Labor Statistics. Analysts expected only 55,000 jobs. It's the biggest job growth in over a year. The gains were led by healthcare, social assistance, and construction. The unemployment rate remained slightly elevated at 4.3%. 92% of Americans like religious themes in movies & TV And finally, a new survey found most Americans are open to religious themes in movies and TV shows. The 2026 Faith & Entertainment Index found 92% of U.S. adults say faith has a role to play in modern entertainment. And 77% believe it can have broad appeal. Brooke Zaugg, executive director of the Faith & Media Initiative, said, “Religion can feel scary to talk about — like politics — so it creates the illusion that it's a small group. That makes it easy for filmmakers to oversimplify it or not give it much thought, instead of recognizing how valuable faith storytelling can be when it's done well.” Close And that's The Worldview on this Thursday, February 12th, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.
What if improving peptides for gut health was one of the missing pieces in helping your body feel more stable and supported? When you live with Hashimoto's, it can feel like you are constantly chasing symptoms. Fatigue, brain fog, food reactions, and unpredictable energy can make daily life harder than it should be. One major piece that often gets overlooked is how much your gut influences your immune system, your energy, and your ability to feel like yourself again. This episode explains why gut function matters so much and why supporting gut signaling may be a key step in moving forward. In this episode, you will learn: Why gut health is a major root cause factor in Hashimoto's How leaky gut can affect immune balance and symptoms How peptide signaling supports gut repair, regulation, and restoration How to tell your body to MAKE more peptides. Naturally. If you are ready to understand how gut repair fits into your bigger Hashimoto's picture, press play on this episode now. Mentioned: Healthy Edge Stack: https://estheryunkin.lifevantage.com/us-en/shop/healthy-edge-stack Hashimoto's Root Cause Reset: https://healthwithhashimotos.com/book-now/ Health with Hashimoto's community on Skool: https://www.skool.com/health-with-hashimotos/about Find all links on my resource page: https://healthwithhashimotos.com/resources/ ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior. This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.
Fatigue, joint pain, brain fog, hair loss, anxiety… and your doctor says your labs are fine. What if your breast implants are the missing piece? In this episode, I join Brandi to explore the truth about Breast Implant Illness (BII) and share essential information to help you understand what to do about this growing health concern. What We Cover:What breast implant illness (BII) actually is and why it's not "in your head"The top reported symptoms of BII to look out for How breast implants increase your risk of autoimmune diseasesMechanisms of breast implant illness like the biofilm theoryThe "rain barrel effect": how long-term immune dysregulation leads to gut issues, nutrient deficiencies, and toxic overloadTimeline of symptom onset with BIIHow to safely remove implantsWhy explant is just the beginning and the next steps to true healingSponsors:EQUIP Prime Protein: https://www.equipfoods.com/NHR15 Save 15% off with code: NHR15Connect with Rachel:Free Health Consultation with Rachel: https://www.naturalhealthrising.net/health-consultationFree Webinar to Heal Your Autoimmune & Mystery Symptoms: https://www.naturalhealthrising.net/webinarJoin the Natural Health Rising community to heal naturally: https://www.skool.com/natural-health-rising-6209/about?ref=77c29ce69cbf4fb2be0865f18fea6bccWebsite: https://naturalhealthrising.com/Support this podcast: https://anchor.fm/rachel-smith11/supportBreast Explant References:[1] Ferreira, S., Barros, A. S., & Marques, M. (2025). Breast Implant Illness: Symptoms, Outcomes with Explantation and Potential Etiologies—A Systematic Review and Meta-analysis. Aesthetic Plastic Surgery, 49(23), 6600–6620.[2] U.S. Food and Drug Administration. (2025, February 6). Medical Device Reports of Systemic Symptoms in Women with Breast Implants.[3] Suh, L. J., Khan, I., Kelley-Patteson, C., Mohan, G., Hassanein, A. H., & Sinha, M. (2022). Breast Implant-Associated Immunological Disorders. Journal of Immunology Research, 2022, 8536149.[4] Watad, A., Rosenberg, V., Tiosano, S., et al. (2018). Silicone breast implants and the risk of autoimmune/rheumatic disorders: a real-world analysis. International Journal of Epidemiology, 47(6), 1846-1854.[5] Adams, W. P., Jr., & Deva, A. K. (2020). Surgical Best Practices: 14-Point Plan. Sientra.[6] DeCesaris, L. (2022, September 22). A Functional Medicine Approach to Breast Implant Illness: BII. Rupa Health.[7] Dreyfuss, D. (n.d.). 8 Tips for a Quick Breast Implant Removal Recovery. Dreyfuss Plastic Surgery.
"I will say that QAnon was right and I was wrong." — Pepper CulpepperFrom Bannon and Trump to Summers, Gates, Blavatnik and Chomsky, the Epstein scandal has revealed elites of all ideological stripes behaving shamefully together. The Oxford political scientist Pepper Culpepper argues this is exactly the kind of corporate scandal that can save democracy—not despite its ugliness, but because of it. His new co-authored book, Billionaire Backlash, shows how scandals activate "latent opinion," bringing long-simmering public concerns to the surface and triggering society-wide demand for regulation. We discuss why Cambridge Analytica led to California privacy law, how Samsung's bribery scandal sparked Korea's Candlelight Protests, and why China's authoritarian approach to corporate malfeasance actually undermines trust.Culpepper, himself the Blavatnik Professor of Government at Oxford's Blavatnik School, acknowledges an uncomfortable truth. "I would say that QAnon was right," he admits, "and I was wrong." The specifics might have been fantasy, but the underlying suspicion about elite corruption was justified. And policy entrepreneurs—obsessive individuals who channel public outrage into actual legislation—matter more than we think. For Culpepper, billionaire backlash isn't a threat to democracy—it might actually be what saves it.About the GuestPepper Culpepper is Vice Dean of the Blavatnik School of Government at the University of Oxford. He is the co-author, with Taeku Lee of Harvard, of Billionaire Backlash: The Age of Corporate Scandal and How It Could Save Democracy (2026).ReferencesScandals discussed:● The Epstein scandal revealed that elites across politics, finance, and academia were connected to Jeffrey Epstein's network of abuse—vindicating populist suspicions that "the system is broken."● Cambridge Analytica (2018) exposed how Facebook leaked data on 90 million users, leading to the Digital Markets Act and Digital Services Act in the EU, and California's privacy regulations.● The Samsung bribery scandal in South Korea led to the Candlelight Protests and President Park Geun-hye's resignation, demonstrating how corporate scandals can strengthen civil society.● The 2008 Chinese milk scandal killed six infants due to melamine contamination; the government's cover-up during the Beijing Olympics destroyed public trust in domestic food safety.● Volkswagen's Dieselgate scandal showed how companies cheat on regulations, bringing latent concerns about corporate behavior to the surface.Policy entrepreneurs mentioned:● Carl Levin was a US Senator from Michigan who shepherded the Goldman Sachs hearings and contributed to the Dodd-Frank Act.● Margrethe Vestager served as EU Competition Commissioner and pushed for the Digital Markets Act and Digital Services Act.● Max Schrems is an Austrian privacy activist who, as a student, discovered Facebook retained his deleted messages and eventually brought down the US-EU data transfer agreement.● Alastair Mactaggart is a California property developer who pushed through the state's privacy regulations when federal action proved impossible.● Zhao Lianhai was a Chinese activist who tried to organize parents after the 2008 milk scandal; the government arrested and imprisoned him.Concepts discussed:● Latent opinion refers to concerns people hold in the back of their minds that aren't front-of-mind until a scandal brings them to the surface.● The Thermidor reference is to the French Revolutionary period when the radical Jacobins were overthrown—Culpepper suggests a controlled version might benefit democracy.● The muckrakers were Progressive Era journalists whose exposés led to reforms like the Food and Drug Administration.Also mentioned:● Michael Sandel is a Harvard political philosopher known for arguing that "there shouldn't be a price on everything."● Patrick Radden Keefe wrote Empire of Pain, the definitive account of the Sackler family and the opioid epidemic.● Lee Jae-yong is the heir apparent to Samsung, implicated in the bribery scandal.● Parasite, Squid Game, and No Other Choice are Korean cultural works that critique the country's relationship with its conglomerates.About Keen On AmericaNobody asks more awkward questions than the Anglo-American writer and filmmaker Andrew Keen. In Keen On America, Andrew brings his pointed Transatlantic wit to making sense of the United States—hosting daily interviews about the history and future of this now venerable Republic. With nearly 2,800 episodes since the show launched on TechCrunch in 2010, Keen On America is the most prolific intellectual interview show in the history of podcasting.WebsiteSubstackYouTubeApple PodcastsSpotifyChapters:(00:00) - (00:22) - The Epstein opportunity (01:21) - Elite overreach exposed (03:12) - Scandals without partisan charge (05:04) - The Vice Dean's credibility problem (06:21) - Latent opinion explained (09:39) - Is there anything wrong with being a billionaire? (11:47) - American vs. European scandals (14:48) - Saving democracy vs. saving capitalism (17:05) - Corporate scandals and economic vitality (18:33) - Policy entrepreneurs: Carl Levin and Margrethe Vestager (19:54...
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce that the company has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next-generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC). Bokhari told Proactive that the Teverelix trial will be conducted as a Phase 2b open-label study enrolling approximately 40 men with advanced prostate cancer who are appropriate candidates for androgen deprivation therapy (ADT). Patients will undergo treatment for approximately 22 weeks. The study's primary endpoint is confirmation of medical castration by Day 29, with sustained testosterone suppression maintained through Day 155. The company is targeting a probability of success exceeding 90% for achieving this endpoint. Teverelix trifluoroacetate is formulated as a long-acting injectable GnRH antagonist delivered as a microcrystalline suspension. Unlike GnRH agonists—which typically cause an initial surge in testosterone levels before suppression—Teverelix works through immediate receptor antagonism. This mechanism enables rapid suppression of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and downstream sex hormones without the testosterone “flare” associated with agonist therapies. This rapid suppression profile may hold particular clinical relevance for patients with advanced prostate cancer who are at elevated cardiovascular risk. Emerging evidence suggests that persistent FSH exposure in patients treated with GnRH agonists may contribute to adverse cardiovascular outcomes. While further clinical validation is required, prior Teverelix studies have not demonstrated significant cardiovascular safety signals to date. Cardiovascular disease remains one of the leading causes of non-cancer mortality in men with prostate cancer, accounting for approximately 30% of deaths. The risk can be further amplified during androgen deprivation therapy, particularly among patients with pre-existing cardiovascular disease. Clinical and observational data indicate that such patients may face a five- to six-fold higher incidence of major adverse cardiovascular events (MACE) when treated with GnRH agonists compared to GnRH antagonists. With FDA clearance now secured, Medicus Pharma is preparing to advance the Phase 2b study as it continues to evaluate Teverelix's potential as a differentiated therapeutic option in the treatment of advanced prostate cancer. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #Teverelix #ProstateCancer #AdvancedProstateCancer #Oncology #ClinicalTrials #Phase2b #FDA #AndrogenDeprivationTherapy #GnRH #BiotechInnovation #CardiovascularRisk #CancerResearch #DrugDevelopment #HealthcareInnovation
Silver, Gold and Crypto (oh my) Hang on – Wild ride here Superbowl, Olympics- Wait until you hear about the CAPex spending! Shakeup in Dietville PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers Warm-Up - Silver, Gold and Crypto (oh my) - Need a stock for CTP - Hang on - Wild ride here - Superbowl, Olympics- Wait until you hear about the CAPex spending! - Shakeup in Dietville Markets - Massive moved during the week - - Bitcoin clipped $60k before rebounding - DJIA tops 50,000 for the first time - Wait until you hear about the CAPex spending! - CAT == 1,100 points on the DJIA in 2026 Superbowl and Superbowl ads - Game review - Any ad stick out? - $10M per ad this year - Half Time with Bad Bunny? - Anthropic busting on OpenAi Last Week! - Massive moved - quick calc showed that about $1T was wiped from market caps in the sell-off, particularly in tech names. - HOWEVER - Friday alone is estimated to have added $1.5T to market cap AI Ripping Through - Plenty of names getting cooked over AI announcements - First it was the software companies - Now there are names in legal and finance that got clocked - Today - Altruist.ai can do tax planning and that hurt companies in financial space Earnings Season Update - Reporting so far: 59% of S&P 500 companies have reported Q4 2025 results. - Beat rate: 76% have topped EPS estimates (vs. 5-yr average: 78% (slightly lower) vs. 10-yr average: 76% (in line) - Magnitude of beats (aggregate): earnings are 7.6% above estimates vs. 5-yr average: 7.7% (about the same) vs. 10-yr average: 7.0% (a bit better) - Nothing great, like Goldilocks Earnings Highlights - Palantir (PLTR): Reported strong Q4 results early in the week , beating estimates with revenue ~$1.41B (vs. ~$1.33B expected) and EPS $0.25 (vs. $0.23). Guidance for 2026 was upbeat (~61% revenue growth). Shares rallied sharply initially (~7–11% post-earnings), but gave back some gains amid broader tech volatility (e.g., down ~11–22% in parts of the week from peaks). - AMD: Reported mid-week, beating EPS (~$1.53 vs. lower expectations) with solid data center growth (~39%). However, Q1 guidance disappointed relative to high expectations in the AI chip space. Shares sank dramatically — down ~15–17% the next day, with some reports noting up to 20%+ drops at points, contributing to broader chip sector pressure. - Alphabet (GOOGL/GOOG): Reported beating on revenue (~$113.8B) and EPS (~$2.82), with strong core performance. But capex guidance for 2026 ($175–$185B, roughly double prior levels) sparked AI spending worries. Shares dipped post-earnings (down ~0.5–5% initially, flat to lower the next day, with some volatility pulling it below key moving averages). - Amazon (AMZN): Reported after hours on February 5, with mixed results — EPS ~$1.95 (narrow miss vs. ~$1.97 expected), but solid overall. The big negative was a surprise $200B capex forecast for 2026 (well above expectations), tied to AI/cloud buildout. Shares plunged sharply — down ~7–10% in after-hours/extended trading, with Friday moves around -5–8% in some sessions. Recent Tech CAPEX announcements - Amazon (AMZN) — Guided to approximately $200 billion in capex for 2026 (a massive jump from ~$125–131 billion in 2025, with ~80% likely AI-related per analyst commentary). This was the largest single-company figure and a major surprise, contributing heavily to the week's "wild" reactions. - Alphabet (GOOGL/GOOG) — Guided to $175–185 billion in capex for 2026 (roughly double the $91 billion spent in 2025, far above analyst expectations of ~$115–119 billion). Emphasis was on AI compute capacity, servers, data centers, and networking to meet demand for Gemini and cloud services. - Meta Platforms (META) — Guidance from late January (but heavily discussed last week): $115–135 billion for 2026 (up significantly from ~$70–72 billion in 2025, potentially an ~87% increase). - Microsoft (MSFT) — No new full explicit 2026 guidance in early February (fiscal year runs July–June), but recent quarterly run-rate and analyst projections put it around $97–145 billion (with some sources citing ~$105 billion or higher based on Q2 spending trends and signals of continued growth from prior levels of ~$88 billion in FY2025). ------!!!!Combined 2026 capex projected at $635–665 billion (low/high ends) or up to $650–700 billion in some reports — a ~60–74% increase from their collective ~$381 billion in 2025. Market Reaction from all of this.... - Markets were a bit spooked on the Anthropic announcement earlier in the week - software sold off and set a sour mood - Microsoft dumped pretty hard as the amount of spend was higher than anticipated, especially with some slower growth in Azure. - Amazon took a beating on the increased spend they anticipate *(extra by $50B) - BUT: Friday markets rallied as there was realization that the $200B spend by Amazon would seep into the economy and fuel infrastructure spending along with chips, tech etc. Other Earnings of Interest - Reddit reported fourth-quarter earnings on Thursday in which the social media company beat on the top and bottom lines. - The company said it expects first-quarter sales to come in the range of $595 million to $605 million, which is higher than Wall Street expectations of $577 million. - Reddit also announced a $1 billion share repurchase program. - Reddit gets about $250 million a year from OpenAi and Google to have your data for training their LLMs While we are on the subject - Friday, DJIA hit 50,000 - first time ever! - Up 1,200 point of which approx 350 was from caterpillar and 280 was from Goldman Sachs Hats off to WalMart - Walmart Inc. shares pushed its market capitalization past $1 trillion on Tuesday for the first time ever| - Big transformation over the pst year - Walmart has maintained its appeal to households looking for value, its online offerings are drawing new, wealthier shoppers seeking convenience. Google Bond Offering - Issuing several tranches of bonds, denominated in Stirling - one as long as 100 years - Would you buy that? - The Google parent is set to raise $20 billion from a US dollar bond offering on Monday — more than the $15 billion initially expected — and is also pitching investors on what would be its first ever offerings in Switzerland and the UK. - The latter would include a rare sale of 100-year bonds, the first time a tech company has tried such an offering since the dotcom frenzy of the late 1990s Fat Profits in Dietville - Really interesting sequence of events happening... - Hims launches compounded pill at prices as low as $49 per month - Analysts cite questions on efficacy, legality of pill - Hims' move shifts focus from Novo's strong Wegovy pill launch - Broader obesity market whipsawed as pricing pressure rises THEN.. - Hims and Hers Health shares dive 14% after hours on Friday (Down 25% on Monday) - FDA cites concerns over quality, safety, federal law - The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers, for its $49 weight-loss pill, including restricting access to the drug's ingredients and referring the company to the Department of Justice for potential violations of federal law. AND.... - Eli Lilly last Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. - The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. - Meanwhile, NOVO had a really bad outlook that took the shares down 13% after the report. Japan Markets Soar - Japanese stocks jumped to a record high Monday, leading gains in the region after Prime Minister Sanae Takaichi won a landmark election victory. - The ruling Liberal Democratic Party captured a two-thirds supermajority in the 465-seat lower house, public broadcaster NHK reported. - Japan's Nikkei 225 jumped past 57,000 for the first time before paring gains to close 3.9% higher at 56,363.94, while the Topix also notched a record high, closing at 3,783.94, up 2.3%. Employment Report? - Government shutdown is forcing them to postpone again (Which is dumb) - Number due this Wednesday - Maybe because of this:U.S. employers announced 108,435 layoffs for the month, up 118% from the same period a year ago and 205% from December 2025. The total marked the highest for any January since 2009. - At the same time, companies announced just 5,306 new hires, also the lowest January since 2009, which is when Challenger, Gray & Christmas began tracking such data. - Also, job openings fell sharply in December to 6.54 million, to their lowest since September 2020. - Available jobs are down by more than 900,000 just since October. - NO! Ai and advancements in tech have noting to do with this! NO NO NO M&A - Texas Instruments Inc. has reached an agreement to buy Silicon Laboratories Inc. for about $7.5 billion, deepening its exposure to several markets for chips. - Silicon Labs investors will receive $231 in cash for each share of the company's common stock and the transaction is expected to close in the first half of 2027. - The transaction still needs to win approval by investors in Silicon Labs and shares of Silicon Labs surged by 51% to $206.48 after the announcement. Inflation - This helps - PepsiCo (PEP.O), opens new tab will cut prices on core brands such as Lay's and Doritos by up to 15% following a consumer backlash against several previous price hikes, the snacks and beverage maker said on Tuesday after it topped fourth-quarter results. Miran - Moving - Federal Reserve Governor Stephen Miran is leaving his post as chair of the Council of Economic Advisers, CNBC has confirmed. - He joined the CEA in January 2025, but had been on leave from that post since last September when he filled the unexpired term of former Fed Governor Adriana Kugler.- He reamins on Fed board No Biggie???? - There are some astonishing cased being reported of Bad AI in the operating room - JNJ's TruDi Navigation System - Since AI was added to the device, the FDA has received unconfirmed reports of at least 100 malfunctions and adverse events. - At least 10 people were injured between late 2021 and November 2025, according to the reports. Most allegedly involved errors in which the TruDi Navigation System misinformed surgeons about the location of their instruments while they were using them inside patients' heads during operations. - Cerebrospinal fluid reportedly leaked from one patient's nose. In another reported case, a surgeon mistakenly punctured the base of a patient's skull. In two other cases, patients each allegedly suffered strokes after a major artery was accidentally injured. Cuba - The main airport has putt out a bulletin that they are out of Jet Fuel - Blackouts and lack of other fuels are creating big problems - No airlines have stopped running at this point, but many will as they cannot refuel - This is a bigger problem for cargo planes (supplies) that may not be able to risk flying to Cuba as they will not be able to get out. Love the Show? Then how about a Donation? ANNOUNCING THE WINNER OF THE THE CLOSEST TO THE PIN CUP 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter
Leveling Up: Creating Everything From Nothing with Natalie Jill
Your CANCER Diagnosis Isn't Your Fault (And Why That Matters): A Stage 4 Cancer Survivor's Truth About Energy and Healing with Maria Kang What if everything you think you know about cancer and healing is actually backwards? Maria Kang has lived a life that defies conventional narratives. She's the "No Excuses Mom" who challenged the fitness industry…and then she got stage 4 cancer while doing everything "right." But instead of following the standard playbook, she made a choice that shocked everyone around her and in that, discovered that cancer wasn't her enemy - it was her greatest teacher. This is not your typical cancer survival story. In this conversation, Maria walks us through her journey from the moment of diagnosis through the stunning realization that cancer, autoimmune disease, and chronic illness emerge from an energetic state of chronic self-betrayal. She shares why she resisted chemotherapy, what happened when the tumor shrank after gratitude practice, why cancer returned, and what truly shifted when she finally surrendered. More importantly, she reveals what this teaches every woman about people-pleasing, boundaries, inner authority, and the cost of abandoning yourself. Whether or not you're facing a cancer diagnosis, this episode will change how you listen to your body. Maria's recent book, Sacred Becoming, documents her full transformation. And what Natalie discovered while reading it is that this isn't just a cancer story, it's a blueprint for remembering who you actually are underneath all the conditioning. Midlife women are in a health crisis not just about food or fitness. It's about chronic disconnection from your own inner knowing. It's about people-pleasing patterns that literally make your body sick. It's about forgotten boundaries and abandoned dreams. Maria's story shows what happens when those patterns escalate to cancer. And more importantly, it shows what becomes possible when you finally listen to your body and remember who you actually are. Episode Links: Maria's new book: Sacred Becoming https://www.sacredbecomingbooks.com/products/sacred-becoming-book Past Episode - 401: The GIFT of Cancer with Maria Kang https://podcasts.apple.com/us/podcast/401-the-gift-of-cancer-with-maria-kang/id1436973433?i=1000673961700 Catch the full episode on YOUTUBE HERE: https://bit.ly/MidlifeConversationsYouTube Learn More About Maria Kang Instagram ➜ https://www.instagram.com/mariakangfitness Website ➜ https://www.mariakang.com/ Book ➜ https://www.sacredbecomingbooks.com/products/sacred-becoming-book Thank you to our show sponsors! QUANTUM UPGRADE: Try Quantum Upgrade completely free for 15 days—no credit card required. Use code NATALIEJILL at checkout on https://quantumupgrade.io/ TIMELINE: Timeline is offering 20% off your order of Mitopure! Go to https://timeline.com/NATALIEJILL Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit For advertising inquiries: https://www.category3.ca/ Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen. Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.
Why calorie counting fails — and why hunger, not willpower, drives eating behavior. Episode #244
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old. Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best! https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live.. the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other. I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporous scaffolds. These are inserted and have been shown to identify changes in cancer, multiple sclerosis, and T1D by capturing changes of immune cells over the course of a disease. This is a proof of concept study in mice.. so very early days. https://www.news-medical.net/news/20260204/Implantable-immune-scaffold-predicts-type-1-diabetes-weeks-before-symptoms.aspx XX A large global genetics study shows that many key drivers of Type 2 diabetes operate outside the bloodstream. In a major international project led in part by the University of Massachusetts Amherst and Helmholtz Munich in Germany, researchers linked hundreds of genes and proteins to the disease. The work, published in Nature Metabolism, points to a key challenge in diabetes research: the biology behind rising blood sugar does not play out the same way in every part of the body. It also shows why including people from many backgrounds matters, since genetic clues that stand out in one population may be faint or invisible in another. Huge study, 2.5 million people worldwide comparing patterns across seven tissues tied to diabetes and four global ancestry groups, then asked a simple question: what do you miss if you only measure blood? Across the seven tissues, the researchers found causal evidence pointing to 676 genes. Yet overlap with blood was limited: only 18% of genes with a causal effect in a primary diabetes tissue, such as the pancreas, showed a matching signal in blood. At the same time, 85% of genetic effects observed in diabetes-relevant tissues were completely absent from blood-based analyses. The findings lay out a roadmap for future research aimed at understanding the biological pathways underlying Type 2 diabetes and developing more effective treatments. https://scitechdaily.com/massive-global-study-rewrites-the-biology-of-type-2-diabetes/ XX Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to changes aimed at lowering costs for patients, insurers and small pharmacies The settlement, first reported by Reuters, fits with that goal, and allows the FTC to pare down a case brought by the former Biden administration against Cigna's Express Scripts, UnitedHealth Group Inc's (UNH.N), Optum unit and CVS Health Corp's (CVS.N), CVS Caremark. The case against Optum and Caremark is ongoing. Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing practices. While the industry has already made reforms, the settlement gives the FTC power to enforce broader changes at Express Scripts. The 10-year agreement restricts Express Scripts' ability to engage in practices critics say contribute to high costs, like pocketing rebate payments from drugmakers based on the list price of drugs. The FTC estimates the agreement could save patients as much as $7 billion over a decade. https://www.reuters.com/world/cigna-settles-ftc-insulin-case-commits-overhauling-drug-pricing-2026-02-04/ XX Audio? Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law. Extends the SDP through December 31, 2026, and increases funding from $160 million to $200 million annually. Strengthens overall funding for the National Institutes of Health (NIH) by $415 million. Increases diabetes research funding at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) by $10 million. Created by Congress and administered by the NIH, the SDP has contributed nearly $3.6 billion to T1D research and has played a role in nearly every major breakthrough in the field. A recent study conducted by Avalere Health shows that of the nearly 3.6 billion invested into the SDP by Congress since the establishment of the program, the Federal Government has realized $50 billion in healthcare savings through improved health outcomes from the use of SDP driven therapies and devices https://www.breakthrought1d.org/news-and-updates/congress-passes-bipartisan-extension-of-the-special-diabetes-program-securing-critical-t1d-research-funding/ XX Dexcom is rolling out what they're calling AI-enabled enhancements to Stelo, further transforming how users track and understand their glucose health. Expanded Smart Food Logging including a comprehensive nutrition database of more than 1M meals that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more. More ways to meal track including text search, barcode scanning or taking a photo of the meal, creating a seamless and intuitive meal tracking solution. A redesigned Daily Insights feature which will introduce a new interface with more personalized recommendations. The newest features will launch nationwide in the coming weeks. XX Beta Bionics has received a warning letter from the Food and Drug Administration following an inspection last year, the company disclosed on Friday. The diabetes technology company said in a securities filing that the warning letter concerns non-conformities with the company's quality management system, medical device reporting, and correction and removals. The warning letter has not yet been posted by the FDA. The company said in the filing that it has already taken actions to improve the processes described in the warning letter, and it is working on a written response to the FDA. The firm does not expect the warning letter to affect the planned launch of a new insulin patch pump by the end of 2027. Beta Bionics unveiled a prototype of the device, called Mint, last year at the American Diabetes Association's Scientific Sessions. The company also does not expect the warning letter to affect its financial results. https://www.medtechdive.com/news/beta-bionics-receives-fda-warning-letter/811140/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue%3A+2026-02-04+MedTech+Dive+%5Bissue%3A81423%5D&utm_term=MedTech+Dive&fbclid=IwY2xjawPwhDZleHRuA2FlbQIxMABicmlkETFaUUcyYmNQWldjZ2xudElic3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHouF8M3IstTyslPRgeHWUWVVdOAGOtzPWt_yNFcj9eYruqSPz3e86Iwcbpt8_aem_7q4D97vJVjHKfEwvoyUpgw XX Sequel Med Tech is reviewing co-founder Dean Kamen's ties to Jeffrey Epstein after recently released documents revealed new details about the longstanding relationship between the two men. The documents show that Kamen visited Epstein's island, and remained in contact with him for years after Epstein was convicted of sex crimes involving minors. Kamen has not been accused of any wrongdoing. In a statement, Sequel Med Tech said the Manchester-based company is aware of the documents pertaining to Kamen and – quote - "Sequel's Board of Directors has unanimously decided to engage an external law firm to review these disclosures and provide recommendations aligned with our mission to serve people living with diabetes," Kamen has not issued a statement regarding his reported connection to Epstein. https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.bostonglobe.com/2026/02/04/metro/nh-dean-kamen-jeffrey-epstein-review/ https://www.nbcboston.com/news/local/nh-inventor-placed-on-leave-after-epstein-messages-surface-report-says/3888569/ XX Abbot reports 860 serious injuries linked to the recall of some of its glucose monitoring sensors. We told you about this recall late last year, these numbers are an FDA update. Abbott said the sensors can provide incorrect glucose readings over extended periods, which could lead to users making dangerous treatment decisions, including eating excessive carbohydrates along with skipping or delaying insulin doses, potentially leading to serious health risks. The company said it has identified and resolved the cause of the issue, which relates to one production line among several that make Libre 3 and Libre 3 Plus sensors. https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-recalls-glucose-sensors-after-seven-deaths-linked-faulty-readings-2026-02-04/ XX Updates from Medtronic & Senseonics – and a first from Nick Jonas.. right after this.. I'm excited to share that the FDA has cleared the MiniMed 780G system with the Instinct sensor, made by Abbott, for people with type 2 diabetes. Medicare has also now approved coverage for the Instinct sensor for use with the MiniMed 780G system. This clearance and expanded coverage mean more people will have access to pairing our most advanced automated insulin delivery technology with the Instinct sensor, that offers a smaller, 15-day sensor experience. They're also launching the MiniMed 780G system Pump Evaluation Program. This program gives individuals living with diabetes the ability to try the full MiniMed 780G system at no cost for 30 days.† This includes the pump, the sensor of their choice, one month of infusion sets and reservoirs, everything but the insulin. They'll contact your doctor for you to get a prescription and get the process rolling. https://www.medtronicdiabetes.com/pump-evaluation-program XX Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval – that's European clearance. This comes on the heels of the launch of Eversense 365 with Sequel Med Tech's twiist pump, marking the first pump integration for the CGM. Senseonics plans to launch Eversense 365 in Germany, Italy, Spain and Sweden in the coming months. Meanwhile, Senseonics continues to work toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year. https://www.drugdeliverybusiness.com/senseonics-ce-mark-eversense-365-cgm/ XX A huge shout out to Dr. Emily Blum, who just accomplished riding 100 miles in Antarctica for Breakthrough T1D! Despite having no direct connection to Type 1 Diabetes, Emily has been riding and fundraising for BreakthroughT1D for 10 years now. She is an integral part of the Georgia Ride team, training and riding many miles, and most importantly has raised tens of thousands of dollars to support the cause of ridding the world of T1D. She is surgeon and deeply involved with medical innovation, with an incredibly busy schedule, but jumped at the chance to take on the challenge of riding a century on every continent. Having already completed North America, Europe, Australia, Asia, and now Antarctica, only Africa and South America remain. Emily rides on and continues to be an inspiration to everyone who meets her. XX https://diabetes-connections.com/t1d-connection-and-people-magazine-elise-zach-share-their-story/ XX Nick Jonas's becomes the first artist ever to wear a CGM on an album cover - new upcoming solo album Sunday Best, releasing Feb. 6. The release says: This marks a powerful step forward in normalizing diabetes and raising awareness for the condition on a global scale. This moment adds to the growing visibility of diabetes in pop culture, alongside milestones like a Type 1 diabetes Barbie and Pixar characters wearing diabetes technology.
A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain's Prime Minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like WeGovy. And SpaceX delays its Mars plans to focus on the Moon instead. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices
Hey Mama, Last week we talked about the importance of drinking water, the damage dehydration can do to your body, and all the amazing benefits of good hydration, not only for your physical body, but also for your ability to manage stress. However, how much water we drink each day can quickly feel like a chore, or one more thing we have to keep track of as busy moms. The truth is, there are ways to build your water consumption into your daily routine, no matter how full it is. Plus, up-leveling your water with essential oils can help you have all day energy and focus for a busy mom. Join me today to learn how to incorporate more water in your day through three simple and stackable habits to help you drink more water for all day energy and focus as a busy mom. Link to the essential oils I use in my water: https://bit.ly/oilsforwater For His Glory, Christen I would love to hear from you! >>Leave a Review >>Connect with me: Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment Email me : naturalwellnessforbusymoms@gmail.com Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094 >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.
Let's dive into the history of P84 with Kelly Olsen — from where it all began to where it is today, and why he chose the network marketing platform to bring it to the world. Don't miss this behind-the-scenes look at the story, the science, and the strategy behind P84. *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the impact of new data showing US Food and Drug Administration hiring increasing, but net employee losses continuing (1:13), including how the issue could be reflected in the user fee program going forward (7:40) and where the strains will emerge as the agency continues to navigate its workload (11:43). More On These Topics From The Pink Sheet US FDA's Drugs, Biologics Centers See Increased Hiring, But Not Enough To Overcome Departures: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-drugs-biologics-centers-see-increased-hiring-but-not-enough-to-overcome-departures-XGMD6U2QHFGULBLCBTRCBWATNQ/ PDUFA VIII: Industry Proposes Funding Changes To Reflect ‘Realistic Ability To Hire Staff': https://insights.citeline.com/pink-sheet/pathways-and-standards/user-fees/pdufa-viii-industry-proposes-funding-changes-to-reflect-realistic-ability-to-hire-staff-AALJBBI5BJEKLEBGIRFL6ZKDQA/ US FDA's Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-failure-to-implement-key-workforce-reforms-puts-oversight-at-risk-gao-says-B64V7RAIQNBNBI57ID5ZU3DYAE/ A Strong Year For US FDA Approvals, But Warning Lights Flashing: https://insights.citeline.com/pink-sheet/product-reviews/approvals/a-strong-year-for-us-fda-approvals-but-warning-lights-flashing-OEYQQ4RRDVHEVPAFYXPQ4LRHOA/
Struggling to get pregnant or stay pregnant with Hashimoto's? You're not imagining it—thyroid issues can quietly sabotage your chances, even when everything else seems "normal." Many women hear "unexplained infertility" or face heartbreaking losses, but the real culprit is often Hashimoto's disrupting ovulation, egg quality, and implantation through hidden pathways like elevated antibodies attacking your uterine lining. The good news? Addressing the root causes gives you a real shot at natural conception and a healthier pregnancy—without rushing to IVF. In this episode, naturopathic fertility expert Dr. Grace Charles breaks it down and shares what actually moves the needle. You'll discover: The three sneaky ways Hashimoto's blocks fertility (from prolactin spikes killing ovulation to autoimmune attacks on your endometrium raising miscarriage risk) Key postpartum red flags—like scary intrusive thoughts or anxiety that hits even when baby's sleeping—that scream "test your thyroid antibodies now" A realistic 6–8 month healing timeline to lower antibodies, optimize labs, and boost your chances of bringing home a baby Ready to stop wondering "why" and start fixing it? Hit play and listen now—you deserve answers and hope. Connect with Dr. Grace Charles Website & free discovery call Free resource: 10 Things You Can Do Today to Improve Your Fertility JOIN THE HEALTH WITH HASHIMOTO'S COMMUNITY Unlock your wellness journey with the free Health with Hashimoto's community! Join a supportive community that's here for you every step of the way. The Health with Hashimoto's community is on Skool: https://www.skool.com/health-with-hashimotos/about Find all links on my resource page: https://healthwithhashimotos.com/resources/ ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior. This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.
Discusses key takeaways from the U.S. Food and Drug Administration's revised Clinical Decision Support Software and General Wellness Product guidance documents. Our guests today are Christina Kuhn and Olivia Dworkin from the law firm Covington. Christina advises medical device, pharmaceutical, and biotech companies on a broad range of FDA regulatory strategy and compliance matters. She has experience with cutting-edge and complex medical technologies, including software and digital health products, oncology products, next-generation sequencing, diagnostics, and combination products. Olivia minimizes regulatory and litigation risks for clients in the medical device, pharmaceutical, biotechnology, eCommerce, and digital health industries through strategic advice on complex FDA issues, helping to bring innovative products to market while ensuring regulatory compliance. Additional resources: FDA's Clinical Decision Support Software guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software FDA's General Wellness: Policy for Low Risk Devices guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-wellness-policy-low-risk-devices 5 Key Takeaways from FDA's Revised Clinical Decision Support (CDS) Software Guidance: https://www.cov.com/news-and-insights/insights/2026/01/5-key-takeaways-from-fdas-revised-clinical-decision-support-cds-software-guidance FDA Issues Revised Guidance on General Wellness Products: https://www.cov.com/en/news-and-insights/insights/2026/01/fda-issues-revised-guidance-on-general-wellness-products Covington Digital Health Blog and Resources: https://www.cov.com/en/practices-and-industries/industries/digital-health CITI Program's Essentials of Software as a Medical Device and Clinical Decision Support Systems: https://about.citiprogram.org/course/essentials-of-software-as-a-medical-device-clinical-decision-support-systems/ CITI Program's course catalog: https://about.citiprogram.org/course-catalog
Eli Lilly Chief Financial Officer Lucas Montarce says their weight loss pill is on track to launch in the US in the second quarter, pending approval by the Food and Drug Administration. Montarce says they “feel good about the progress.” He speaks to Katie Greifeld.See omnystudio.com/listener for privacy information.
This Day in Legal History: FDR's Court Packing PlanOn February 5, 1937, President Franklin D. Roosevelt proposed the Judicial Procedures Reform Bill of 1937, better known as the “court-packing plan.” This controversial legislation aimed to expand the number of justices on the U.S. Supreme Court from nine to as many as fifteen. Roosevelt's justification was to improve the efficiency of the judiciary, but the underlying motive was widely understood to be frustration with the Court's consistent invalidation of New Deal legislation. The plan would have allowed the president to appoint an additional justice for every sitting justice over the age of 70½ who refused to retire.At the time, the Supreme Court had struck down several key components of Roosevelt's New Deal, including the National Recovery Administration and the Agricultural Adjustment Act. Although Roosevelt had just won re-election in a landslide in 1936, the proposal met immediate and bipartisan resistance in Congress and the press. Critics argued it threatened the separation of powers and judicial independence. Even members of Roosevelt's own party viewed the move as a dangerous overreach.Ultimately, the bill failed in the Senate. However, the controversy arguably pressured the Court to adopt a more favorable view of New Deal legislation. Justice Owen Roberts's shift in support of certain New Deal programs came to be dubbed “the switch in time that saved nine.” While Roosevelt did not get to add new justices through his plan, he eventually appointed eight Supreme Court justices over his long presidency, reshaping the Court over time.Georgia's Fulton County has filed a legal challenge over an FBI seizure of 2020 election records, arguing the search was overly broad and requesting the return of the documents. The motion, filed in federal court, also seeks to unseal the affidavit behind the warrant. The FBI searched the Fulton County Election Hub in Union City on January 28 as part of its investigation into President Donald Trump's false claims of widespread voter fraud in Georgia during the 2020 election, which Trump lost to Joe Biden. According to the warrant, agents were authorized to confiscate all physical ballots, tabulator tapes, and voter rolls from multiple voting methods. County Commissioner Marvin Arrington Jr. criticized the process, noting the absence of an inventory or orderly transition of records, which raises concerns about potential document loss or tampering. He expressed skepticism about the value of any returned materials under such circumstances. The raid, perceived by local officials as politically motivated, has sparked fears of federal overreach and interference ahead of the 2026 midterms.Georgia's Fulton County challenges seizure of election records | ReutersJones Day, a major international law firm, has filed a lawsuit in New York state court against private equity firm Centre Lane Partners and multiple affiliated companies, alleging over $9.6 million in unpaid legal fees. The firm claims it served as Centre Lane's outside counsel since 2018, providing legal services across litigation, financing, acquisitions, and regulatory matters. Though Centre Lane reportedly had a consistent payment history, Jones Day alleges payments ceased in 2024 despite continued promises. Relying on assurances that payments were forthcoming, Jones Day says it rendered millions more in services, which it now claims were based on false representations.Notably, more than half of the unpaid fees stem from Jones Day's defense work in an ongoing antitrust case involving a Pennsylvania glass plant closure and an FTC investigation. As of last month, Jones Day began formally withdrawing from representing Centre Lane in active cases, and the law firm Greenberg Traurig has taken over in the antitrust matter. Among the defendants named are Centre Lane portfolio companies, including Anchor Hocking and Corelle Brands. The case remains unassigned in New York's Supreme Court, with no counsel yet listed for the defendants.Law firm Jones Day sues private equity firm, alleging $9.6 million in unpaid fees | ReutersThe U.S. Food and Drug Administration has classified Abbott's recall of certain glucose monitoring devices as a Class I recall—the most serious level—after the products were linked to seven deaths and 860 serious injuries. The affected devices include specific lots of the FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors, which have been found to display inaccurately low blood sugar readings. Such faulty readings can lead users to make harmful treatment decisions, such as consuming too many carbohydrates or incorrectly adjusting insulin doses.Abbott disclosed that the devices may provide incorrect readings over extended periods, increasing the risk of serious medical complications for users who rely on continuous glucose data. The recall and its classification signal heightened concern from federal health regulators due to the potential for severe harm or death. As of early January, these issues had already caused significant patient harm. Abbott has not publicly detailed the total number of units affected or the geographic scope of the recall.Abbott recalls glucose sensors after seven deaths linked to faulty readings | ReutersIn an exclusive obtained by Bloomberg Law, the U.S. Department of Justice has directed all 93 U.S. attorney's offices to designate prosecutors for newly formed “emergency jump teams” by February 6. These teams are intended to provide short-term support in jurisdictions experiencing critical events—particularly those involving alleged assaults on or obstruction of law enforcement. The internal memo from DOJ Executive Office Director Francey Hakes outlines the initiative as a rapid-response measure to bolster prosecutorial presence in areas facing urgent demands.The move follows a wave of resignations in the Minneapolis U.S. attorney's office amid growing discontent over political targeting and controversial assignments, such as a disputed investigation into the widow of a protester killed by an ICE officer. While the memo does not directly mention Minneapolis, it aligns with Trump administration efforts to maintain aggressive law enforcement in left-leaning jurisdictions facing staff shortages.Offices previously affected by similar surges, including Chicago, Los Angeles, and D.C., have also suffered attrition, partly due to repeated grand jury refusals to indict protestors. The memo frames the jump teams not as litigators but as support staff to assist in command operations—handling triage, reviewing legal filings, and managing logistics.The order coincides with overt recruitment of ideologically aligned attorneys, including a public social media call for applicants who support Trump's anti-crime platform. Additionally, the jump teams will help implement Attorney General Pam Bondi's December directive to prioritize investigations into leftist groups like antifa.DOJ Orders Emergency Surge Prosecutors From All US Attorneys (2) This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe
In this episode of 1st Talk Compliance, Kevin Chmura is joined by Robyn Johns, as they discuss recent updates to their November live webinar, Compliance Cliffs: Navigating Telehealth Waivers and Reimbursement Changes. Learn how the policy landscape has shifted in recent months—especially around telehealth flexibilities, controlled substance prescribing, and the 2026 CMS payment rules. Kevin Chmura Welcome to 1st Talk Compliance. I’m Kevin Chmura, CEO of Panacea Healthcare Solutions. Today we’re bringing you a timely update on our November live webinar, Compliance Cliffs: Navigating Telehealth Waivers and Reimbursement Changes. Since that webinar, several policy changes have moved quickly, especially in telehealth flexibilities. Controlled substance prescribing and 2026 CMS payment rules. Before we jump in, just a quick note. 1st Talk Compliance is brought to you by 1st Healthcare Compliance, a part of Panacea Healthcare Solutions. We help healthcare organizations strengthen their compliance programs with practical education tools and compliance management support. So teams can reduce risk, keep pace with regulatory change and operate with confidence. Now I’m pleased to welcome back Robyn Johns from Med USA. Robyn, thanks for coming back. Robyn Johns Thanks, Kevin. I’m happy to be here. Kevin Chmura Great. So, let’s jump in. So, in November on the webinar, we spent a lot of time on what people were calling the telehealth cliff, which was creating a tremendous amount of uncertainty on whether flexibilities would expire. Can you catch us up on what the status is now? Robyn Johns Yeah. The major update is that the spending package released on January 20th includes extensions of the telehealth flexibilities all the way through December 31st of 2027. Kevin Chmura So that’s a pretty meaningful runway. That’s great, but I guess doesn’t eliminate compliance obligations, but it is reducing near-term uncertainty which give everybody some time to standardize workflows. So, it’s in the news, but maybe you could tell. So, what’s in the spending package at a high level and what should healthcare leaders like us be paying attention to? Robyn Johns Right. So, it was the one from the 20th was a $1.2 trillion spending package released by the House Appropriations Committee and it was just passed yesterday on the 22nd in two separate votes by the full House. So, those bills included the remaining six of the twelve appropriations necessary to avert a government shutdown. So that’s good news for everyone. If we can get them across the finish line, they funded many of the federal government agencies such as HHS, Labor, Defense, HUD, and also Homeland Security. That was a contentious one. That’s why they had to do two separate votes. It funds them through fiscal year 2026, which ends on September 30th of this year. Kevin Chmura So, OK, so we have a funding package with multiple healthcare policy riders. Not, I guess not too surprising in today’s day and age. So, besides the telehealth through 2027, what else is included in there that compliance and operational leaders should know about? Robyn Johns So the writers also include PBM reform and it extends hospital at home actually through 2030, which is another one that hit a lot of facilities hard with the government shutdown. It extends Medicare dependent hospital and low volume hospital programs, which is really beneficial for our rural providers and it delays the Medicaid disproportionate share cut again until fiscal year 2028. Notably, for a lot of people, it does not include an extension of the ACA subsidies, which were such a sticking point in the government shutdown last fall. Kevin Chmura Yeah, that that that last point is operationally really important and coverage instability often turns into eligibility churn and puts real pair mix pressures on the you know same patients, different coverage, right.? And that’s just you know probably increases downstream compliance and documentation stress. Yeah that’s a that’s a tough one. So what’s the timing of congressional action now? Robyn Johns So with the House passing all of the bills, they now send the full appropriations package to the Senate. The Senate will take all of that up when they return from recess on Monday the 26th, and will hopefully pass them all ahead of the January 30th deadline. And hopefully without any significant changes which might require them to go back to the house because the house will be on recess next week. Kevin Chmura Wow. So split schedule, it’s why we should keep ourselves in a monitoring posture. I guess we should always be monitoring, but things are moving pretty quickly right now and you sort of get into that world of what is expected is not what’s in effect. Which is always, always a tough place to operate, but hey, that’s healthcare, isn’t it? So, given the extension to 2027, in your opinion, what should compliance teams be doing now? Like what’s some practical next steps? Robyn Johns First, you’ll want to make sure that your internal policies and educational materials reflect what’s currently in effect. No major changes since most of those telehealth things were extended, but it’s always good to double check because lots of things change around the beginning of the year. Also validate your payer specific rules. Medicare policy direction is influential, but commercial payers and state laws differ. So, you got to make sure that you are matching up with those differences. And then third, we should we talk about strengthening your auditing of documentation, the modifiers, your place of service, medical necessity, all of those things that can vary depending on the payer and the specific situation of the patient. Kevin Chmura Yeah, that that payer variation point is where a lot of organizations end up being exposed, I guess, right? Telehealth’s not really governed by one rule. You’ve got federal policy, state overlays, and then you have commercial policy updates really coming at you a number of different ways. So, I guess a good controls to maintain maybe a payer policy matrix and try to align it into your documentation and coding guidance. Probably a solid piece of advice. Robyn Johns Absolutely. Kevin Chmura Yeah. So, let’s move on to probably one of the highest risk areas that we covered in the webinar, and that’s controlled substance prescribing via telehealth. What’s the latest there? Robyn Johns Good news there as well. At the end of the year, DEA and HHS extended the telehealth flexibilities for prescribing controlled substances through this year, December 31st of 2026. There are a few rules that can apply, but because they extended the flexibilities, it’s pretty much status quo until they change it again at the end of the year. Kevin Chmura Cool, so that’s a critical compliance area because of the high risk profile and it that really includes some regulatory scrutiny and enforcement, not really just a reimbursement issue. Robyn Johns Yes, it’s highly watched. Kevin Chmura Yeah. And I guess as well, it should be. So given that, what control should organizations prioritize right now to reduce risk in that area? Robyn Johns Definitely you’ll want to have clear prescribing policies, good documentation standards, and role-based training. Also, usually they want to include identity verification and required checks when they’re applicable, and consistent auditing to ensure that your process is followed, not just written down. This is another area where state regulations can vary, so you would want to make sure that you are compliant in every state where you see patients. Kevin Chmura Yes and you’re the expert, not me. But I guess I’d add if you expand health to if you expand the telehealth quickly, take time now to ensure your governance is mature. And I’m thinking credentialing, supervision, documentation and audit trails always the basics that can help you pulled up under scrutiny. Robyn Johns Definitely. When you expand quickly, sometimes you sacrifice certain things for speed. So, you have a minute now to go back now that you’re sure that those policies aren’t changing anytime soon to just go back and make sure that everything’s in place, all of those areas. Kevin Chmura Yeah, I mean like any business runs better and with certainty, but at healthcare we rarely have that. So, great. So, moving on to the 2026 CMS updates that that we talked about a little bit. So, there’s been some changes in payment policy that are driving operational changes and it’s where those operational changes come in, where we introduce compliance risks if teams can’t keep pace and often they can’t. So, what are the 2026 physician fee schedule highlights? Robyn Johns Yeah. So, we talked about these back in November and of course they went into place at the beginning of this year. So, a little bit of good news there with the conversion factor. It included the 2.5% increase that had been mandated by Congress. It also included a .75% increase for clinicians in advanced APMs or a .25% increase for clinicians who participate in MIPS or who are exempt. And then there was also a .49 budget neutrality increase. Kevin Chmura So, so the real impact varies by payer mix, site of service and quality of participation. What about RVU related changes? Robyn Johns So that’s kind of the devil in the details there. It also implemented a -2.5% efficiency adjustment on certain non-time based services to the physician work RVU and there is also a + or -50% practice expense RVU adjustment for facility based services. So, it’s -50% if it’s facility based services or a +50% for non-facility based services. Kevin Chmura Wow. So site of service is increasingly strategic and it’s where we see compliance issues often arise, right? You get inconsistent documentation, coding and policy adoptions across different departments and locations. Certainly not easy. Robyn Johns No. Something you definitely need to watch closely because it is different depending on where you are and what services you’re providing. Kevin Chmura Yeah. So, one other hotspot or another hotspot that that we often see is incident to. What's going on there? Robyn Johns So the physician fee schedule in that they updated the definition of direct supervision for incident to billing to permanently allow supervision through real-time audio video communication except for services that have a 10 or a 90-day global surgery period. So, the supervising physician no longer has to be physically present in the office suite, they just have to be immediately available through real time audio video communication. Kevin Chmura OK, so that’s operationally pretty significant, right? But I guess the compliance take away is relatively simple. If you’re using remote supervision, your incident to workflows must be precise. I guess who supervises, how it’s documented, and where the exceptions apply as precise as you can make all of those, huh? Robyn Johns Yes, absolutely. Because you are relying on remote supervision, you’ll want to make sure that that is documented very effectively. Kevin Chmura Yeah, cool. So, what about the OPPS and ASC final rule highlights for 2026? Robyn Johns Yeah. For those that these apply to, there was a 2.6% increase as well in the payment rates. They also expanded hospital price transparency requirements and we’re seeing a lot more attention and probably enforcement in that as well. There was a three-year phase out of the inpatient only list. Site neutral payments were expanded to include Drug Administration Services and the ASC covered procedures list is expanded much in relation to the inpatient only list Phase out. Kevin Chmura Yeah, that that that that’s an interesting one. So the phase out of the inpatient only list is a real operational shift and it’s one of those opportunities for providers to move volume to better cost locations, but really your compliance needs to follow those patients, right and where you’re having them. And so, when your volume moves, audits and education have to move with it, which is probably a challenge and what we know and we at our parent company, at Panacea, price transparency just remains a compliance and reputational priority because failures lead to penalties, but bad data also leads to a lot of scrutiny. So, good that there’s some, you know some guidance there, but it’s clear that those are going to be things that really need to be paid attention to from a compliance perspective. Robyn Johns Yes, for sure. Kevin Chmura So it was hard to watch the news over the last, I don’t know, six to twelve months without talking about the One Big Beautiful Bill Act. So, we’ve been tracking it. I know you’ve been tracking it. So, what’s the timing on practice impacts that you expect? Robyn Johns So most of those One Big Beautiful Bill Act Medicaid requirements that are likely to impact practices, they don’t actually begin until January of 2027. So, practices still have some time to continue their assessment and preparation for those. The immigrant eligibility changes do take effect on October 1st of this year, 2026. So that’s a little bit shorter period of time, but you do have a little bit of time to continue to figure out how that may affect your practice if you have a high number of Medicaid patients, and prepare for the ways that you can offset those eligibility changes and payment requirements. Kevin Chmura Yeah, that clarity on the effective dates really can help teams allocate resources correctly and that’s often a challenge especially when you’re tracking proposed rules versus final rules and not sure when things will go into effect. So that’s good. So, as you’re looking out on the landscape in 2026, what are some of your top compliance priorities that you’re advising organizations to focus on? Robyn Johns Yeah, we’re currently focused on probably five or so top priorities for 2026, not in any specific order, but we are watching data privacy and security. Part of that is because HIPAA updates are underway to both the privacy and security rules, though timelines are unclear. We’re not sure when or i f we’ll see any final rules on those, but we do know that healthcare remains a prime target of cyber-attacks, so we have to constantly be vigilant to that and related to that, but also separately, is AI and other emerging technologies. AI is changing the landscape for the types of attacks we receive, but also the way we have to respond to them. It also is changing the landscape of healthcare generally, both in the provider office and at the payers and at the government. Those other emerging technologies like digital tools, those can increase the compliance risk in your environment, and we need to remember that both government and commercial payers are using AI to identify outlier claims faster and increase their auditing. Then we also have the fraud, waste and abuse enforcement. CMS we know has currently been focused a lot on Medicare Advantage, but that scrutiny can shift oversight over to providers as well because that’s where so much of the data that the Medicare Advantage plans use comes from. The OID also continues to focus on telehealth. There are other focuses are drug device and biologics and program integrity areas such as DME, Hospice and Drug Administration. So, want to make sure that you’re watching all of those if you practice there. Fourth one we have is vendor and third-party oversight. Many of the largest breaches that have we’ve seen have originated with third parties. So, organizations really need to make sure that you have careful oversight and maintain good monitoring on your third-party vendors and others who may have access to your systems and data. And finally, we know we’re going to continue to see those rapid regulatory updates. Federal and state changes often conflict. We have lots of states that are currently in their legislative period. So that will bring out some changes. And then in addition to that, commercial payers are tightening their policies and auditing in response to the pressures that are being put on that on them, whether from the government or just from a financial perspective. Kevin Chmura Yeah, it is something the pace of acceleration of some of the advances in technology and how they how they’re going to impact us. But I guess you know that’s really the reality of 2026 and beyond. You’re going to see an uptick in in in speed to policy changes, faster detection, which will be something and probably more third-party exposure as we rely on more and more vendors and others to help us do what we need to do every day, but I’m sure you know the advice I’ve heard you give many times and we have to agree with it. A strong compliance program has to be built to adapt. That means clear governance, repeatable monitoring and targeted auditing tied to the current risk with an eye on the future and where everything’s going. Robyn Johns Yeah, definitely. It’s an exciting time, lots of opportunities for improving our programs and really tightening things up to make sure that we’re protecting ourselves and all the information that we are responsible for. Kevin Chmura Yeah, great. So, Robyn, thank you for the update and for helping our listeners translate policy movement into practical compliance actions. To everyone listening, if you want the full context and deeper discussion, you can access the webinar on demand at 1st Healthcare Compliance’s website. It’s called Compliance Cliffs: Navigating Telehealth Waivers and Reimbursement Changes. Thank you for listening to 1st Talk Compliance and we’ll see you next time. Thanks, Robyn. Robyn Johns Thanks, Kevin.
Leveling Up: Creating Everything From Nothing with Natalie Jill
Get Ari Whitten's Book here: https://theenergyblueprint.com/referral.html?p=nataliejill&w=RLTBookLaunch What if the most effective anti-aging tool isn't some skincare in your cabinet but is something that has been scientifically proven for 30 years, studied across 6,000 peer-reviewed research papers, and yet nobody told you about it? What if the reason you haven't heard about it isn't because it doesn't work, but because the science moved faster than the system? In this episode, I'm sitting down with Ari Whitten, one of the world's leading experts in photobiomodulation and red light therapy. Ari and I have known each other for nearly two decades. What he's discovered about light, cellular energy, aging, and mitochondrial health has genuinely transformed how I approach my own health. That's why I'm bringing him back to share this information with you. We're diving deep into topics that matter: Is red light therapy actually scientifically proven, or is it just the latest wellness trend? (Spoiler: 6,000 peer-reviewed studies, 30+ years of research, and now mainstream adoption says it's proven.) How does red light actually work at the cellular level? (Hint: it's not magic, it's mitochondrial biology.) Why are dermatologists still recommending sun avoidance when red light from the sun is protective? (And how do you know which wavelengths actually age you?) Which devices actually work, which ones are a waste of money, and how do you know the difference? (Device selection matters more than most people realize.) How can red light therapy support anti-aging, energy, recovery, sleep, and brain function all at the same time? (It's not separate benefits, it's connected cellular biology.) Why don't doctors talk about this if the science is solid? (The answer reveals a lot about how medicine actually works.) How does diet work synergistically with red light therapy for skin health? (Your vegetables are doing more for sun protection than you realize.) Your body hasn't evolved to live under artificial lights all day and then in bright LED light all night. It's evolved to sync with the sun. But the sun's effects on your health depend on understanding which wavelengths you're getting and what they actually do. Red light therapy isn't a new invention. It's 30 years of proven science finally becoming mainstream. When you align your light exposure with natural cycles, strategically use red light therapy for specific goals, and support your skin with proper nutrition, you're not just optimizing. You're addressing one of the most fundamental inputs to human health that most people completely overlook. The science isn't new…public understanding of it is just catching up.
A practical conversation about why goals don't create change — daily actions do. Episode #243
Hey Mama, When we want energy as busy moms, we often want to reach for our favorite all natural energy drink, drive through for our favorite latte or heat up water for some nice tea. However, many of us have become so dependent upon caffeine to fuel us that it may be causing you more harm than good. It's true, your coffee or Alani fix may be exacerbating your stress and anxiety. Listen in today to learn why you should prioritize daily hydration as a stressed out mom. For His Glory, Christen I would love to hear from you! >>Leave a Review >>Connect with me: Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment Email me : naturalwellnessforbusymoms@gmail.com Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094 >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.
February is packed with momentum at LifeVantage! In this episode, Mindy sits down with Victor and Dr. Tamia to break down everything happening this month—from the excitement around Momentum Academy and our latest product launch to how Activate90 can help you stay consistent with your health and business goals. Tune in for key updates, insights, and simple ways to plug in and make the most of what's ahead. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consultants earnings and incentives will depend on individual diligence, work effort, and market conditions. LifeVantage does not guarantee success. See qualifications for additional information.
This episode addresses the growing challenge of adolescent obesity, which now affects over 22% of US teens. The discussion highlights Food and Drug Administration-approved pharmacotherapy options for adolescents, considerations for side effects and monitoring, and the importance of pairing medications with lifestyle interventions. The episode also explores strategies for providing patient-centered, bias-free care and engaging families in long-term weight management. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
In this encore episode, we highlight vitamin D₃ in gastrointestinal health, with a focus on intestinal barrier function and the gut-immune axis. We discuss how vitamin D is metabolized into its active form, 1,25-dihydroxyvitamin D, and how 1,25-dihydroxyvitamin D can support intestinal health, while highlighting intestinal mucosal anatomy.Topics:1. Introduction - Highlighting intestinal barrier function and the gut-immune axis with a focus on vitamin D₃ 2. Vitamin D Synthesis and Metabolism - Skin and 7-dehydrocholesterol; dietary intake.- Transported through the bloodstream bound to vitamin D binding protein.- First hydroxylation in the liver to form 25-hydroxyvitamin D₃ (25(OH)D₃).- Testing.- Second hydroxylation in the kidney to form the active 1,25 dihydroxyvitamin D₃ (1,25(OH)₂D₃).- Local activation also occurs. 3. Intestinal Barrier Anatomy - The intestinal epithelium forms a selectively permeable monolayer that interfaces with the gut lumen.- Covered by a mucus layer.- Tight junction proteins and paracellular permeability.- The lamina propria and Gut-Associated Lymphoid Tissue (GALT). - Maintaining tolerance. 4. Vitamin D - 1,25-dihydroxyvitamin D₃, tight junction integrity, immune regulation, and more. 5. Vitamin D₂ and D₃ 6. Conclusion - Neither too high nor too low: optimal levels.- Multifactorial: Numerous factors regulate vitamin D levels.- Gastrointestinal health root cause approach.Thank you to our episode sponsor: 1. "Longevity" with Protein, Probiotics, Bovine Colostrum, Collagen, and More. Use code CHLOE for 25% off.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.Thanks for tuning in!Follow Chloe on Instagram @synthesisofwellnessVisit synthesisofwellness.com
Have you been told gut health matters for Hashimoto's, but felt overwhelmed trying to figure out where to start or what actually fits your life? If you have Hashimoto's, gut health is not optional. It is one of the most common root causes behind fatigue, brain fog, mood changes, and feeling unlike yourself. But improving gut health does not require perfection, complicated testing, or doing everything at once. This episode breaks down simple, doable steps (good, better, best) so you can pick what fits your life right now. Press play to listen to the full episode and learn how to improve gut health with Hashimoto's in a way that feels sustainable and doable. Get Seed (affiliate link. Save $25) https://refer.seed.com/by/yunkin@mac.com Or on FullScript: https://us.fullscript.com/welcome/eyunkin The Healthy Edge - What is it: https://biohackandactivate.com/p84 Order: https://estheryunkin.lifevantage.com/us-en/shop/healthy-edge-stack JOIN THE HEALTH WITH HASHIMOTO'S COMMUNITY Unlock your wellness journey with the free Health with Hashimoto's community! Join a supportive community that's here for you every step of the way. The Health with Hashimoto's community is on Skool: https://www.skool.com/health-with-hashimotos/about Find all links on my resource page: https://healthwithhashimotos.com/resources/ ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior. This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.
Leveling Up: Creating Everything From Nothing with Natalie Jill
What if the hormone advice you're following is actually making everything worse? In part two of this conversation, Dr. Betty Murray returns to expose the dangerous myths keeping midlife women stuck in hormone chaos. This conversation goes deep into the truth about estrogen dominance versus estrogen deficiency, why your testosterone dose might be creating more problems than it solves, and the critical difference between total and free hormone levels that most doctors completely miss. We're talking about the three stages of the menopause transition and what's actually happening to your hormones during each phase. Dr. Murray explains why that single lab test your doctor ordered probably tells you almost nothing useful, especially if you're in perimenopause when your hormones are doing "the bungee cord" - jumping from 600 one day to 40 the next. You'll discover why cycling progesterone might be making your life unnecessarily complicated and destroying your sleep, how environmental toxins are sitting in your estrogen receptors right now if you're not on adequate hormone replacement, and the real truth about soy that has nothing to do with the wellness industry scare tactics. This episode also tackles the GLP-1 medication controversy head-on. Dr. Murray shares why these drugs are being dangerously misused for rapid weight loss when they could be valuable longevity tools at lower doses, and why the real problem isn't the medication itself but the eating disorder culture we're creating around it. Plus, we dive into peptides: what they actually are, why they're exploding in the longevity space, and why taking them without proper guidance could shut down your body's natural hormone production. If you've been told your hormones are "fine" while feeling anything but fine, or if you're on hormone therapy but still struggling with symptoms, this conversation will change how you understand and advocate for your hormone health. Listen to the full episode to discover exactly what your body needs to thrive in midlife. Catch the full episode on YOUTUBE HERE: https://bit.ly/MidlifeConversationsYouTube Learn More About Dr. Betty Murray Instagram ➜ https://www.instagram.com/drbettymurray Website ➜ https://gethormonesnow.com/nataliejill Thank you to our show sponsors! BEAM: Level up your health with BEAM Minerals at https://midlifeconversations.com/beam and use code NATALIEJILL to save! SUNLIGHTEN: Sleep better. Recover faster. Stress less. Get Sunlighten infrared saunas HERE https://sunlighten.com and use code NATALIEJILL to save up to $1,400! Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit For advertising inquiries: https://www.category3.ca/ Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen. Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.
A practical coaching conversation for new fasters on why slowing down is the fastest way to make real progress. Episode #242
BREAKING NEWS:The Food and Drug Administration announced it is taking steps to Improve Gluten Ingredient Disclosure in Foods by issuing an Request or Information (RFI) regarding labeling Gluten and preventing cross-contact of Gluten in packaged food.Eighty seven other countries require the labeling of Gluten (Wheat, Barley, Rye and Oats). Since 2006, only Wheat has been required to be labeled, but but Barley, Rye and Oats. The US needs to catch up with the rest of these countries.Here's how you can help:The FDA is allowing 60 days for feedback and comments on the RFI. Specifically the FDA is seeking information on adverse reactions due to "ingredients of interest" (i.e., non-wheat gluten containing grains (GCGs) which are rye and barley, and oats due to cross-contact with GCGs) and on labeling issues or concerns with identifying these"ingredients of interest" on packaged food products in the U.S."People with celiac disease or gluten sensitives have had to tiptoe around food, and are often forced to guess about their food options," said FDA Commissioner Marty Makary, M.D., M.P.H. "We encourage all stakeholders to share their experiences and data to help us develop policies that will better protect Americans and support healthy food choices."PLEASE take a few minutes and leave your comment hereI would love to hear from you! Leave your messages for Andrea at contact@baltimoreglutenfree.com and check out www.baltimoreglutenfree.comInstagramFacebookGluten Free College 101Website: www.glutenfreecollege.comFacebook: http://www.Facebook.com/Glutenfreecollege Hosted on Acast. See acast.com/privacy for more information.
About this episode: The U.S. Food and Drug Administration is responsible for reviewing the safety and effectiveness of vaccines—a job that requires deep scientific understanding as well as thoughtful regulatory judgment. In this episode: Dr. Jesse Goodman, a former top vaccine regulator and chief scientist at the FDA, explains how the agency came to lead the world in vaccine oversight—and shares his concerns for the future. Guests: Dr. Jesse Goodman, MPH, is a professor and the director of Georgetown University's Center on Medical Product Access, Safety and Stewardship. He worked at the FDA from 1998 until 2014, including as chief scientist. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: How HHS, FDA, and CDC Can Influence U.S. Vaccine Policy—KFF Vaccines 101—Johns Hopkins Bloomberg School of Public Health Recent "Expert Panels" Could Undermine the FDA's Credibility—Public Health On Call (September 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @PublicHealthPod on Bluesky @PublicHealthPod on Instagram @JohnsHopkinsSPH on Facebook @PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
Hey Mama, We know true peace can only come from the One Who Is Peace. If we want peace, we must seek God first. Trouble is, it is easy to become consumed by the busyness of motherhood and life. Maybe you want to spend more time in God's word, but then someone gets sick, or you over-sleep, or your carefully crafted schedule suddenly morphs into chaos. However, I have learned that no matter how busy my schedule, I can find at least 10 minutes each day to spend with God, and you can too. It's time to restore calm in chaos, one step at a time. For His Glory, Christen I would love to hear from you! >>Leave a Review >>Connect with me: Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment Email me : naturalwellnessforbusymoms@gmail.com Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094 >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.
In this podcast episode, Shannon Hill, Nissa Van Etten, and Jordan Fries interview Thomas Frazier about outcome measurement in behavioral intervention services. Using Frazier and colleagues' work on adaptive social communication measurement as a foundation, the discussion explores why many legacy assessments were not designed for the ABA context or for individuals with autism and developmental disabilities. The presenters distinguish between moment-to-moment ABA data collection and periodic outcome assessment, highlighting how periodic measures support long-term progress tracking, clinical decision-making, and accountability to funders. The episode emphasizes the complementary roles of norm-referenced and skill-based assessments, discusses constraints such as limited assessment authorizations, and underscores the importance of monitoring client and family quality of life. Ethical considerations related to caregiver-report measures, interpretation of sensitive results, and appropriate referrals are also addressed. To earn CEUs for listening, click here, log in or sign up, pay the CEU fee, + take the attendance verification quiz to generate your certificate! Don't forget to subscribe and follow and leave us a rating and review. Show Notes: References Frazier, T. W., Youngstrom, E. A., Frazier, A. R., & Uljarevic, M. (2025). A critical appraisal of the measurement of adaptive social communication behaviors in the behavioral intervention context. Behavioral Sciences, 15(6), 722. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89(5), 485–491. Sparrow, S. S., Cicchetti, D. V., & Balla, D. A. (2005). Vineland Adaptive Behavior Scales (2nd ed.). Circle Pines, MN: American Guidance Service. Abidin, R. R. (2012). Parenting Stress Index (4th ed.). Lutz, FL: Psychological Assessment Resources. Resources U.S. Food and Drug Administration. (2022). Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments—Guidance for Industry, FDA Staff, and Other Stakeholders. International Consortium for Health Outcomes Measurement (ICHOM). Autism Spectrum Disorder Standard Set. Child and Family Quality of Life (CFQL) Measure.
Welcome to Fertility & Sterility Roundtable! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility & Sterility. This week, we welcome Dr. Paula Amato and Professor Glenn Cohen to discuss the legal and ethical implications of in vitro gametogenesis (IVG) - the creation of human eggs and sperm in a laboratory setting using non-reproductive cells, such as skin or blood cells. Through our discussion, we will explore several issues raised by this nacent technology, including safety, Food and Drug Administration review, embryo destruction, eugenics, enhancement, unauthorized parenthood, inequitable access, and evolving conceptions of parenthood. Dr. Paula Amato is Professor of Obstetrics & Gynecology and Director of the Division of Reproductive Endocrinology & Infertility at Oregon Health & Science University. She received her medical degree from the University of Toronto in Canada, where she also completed her Residency in Obstetrics & Gynecology, followed by a Fellowship in Reproductive Endocrinology & Infertility at the University of California, San Diego. Dr. Amato is past-president of the American Society for Reproductive Medicine. Her research focuses on innovative assisted reproductive technologies for the treatment of infertility and ovarian aging. Professor Glenn Cohen is the James A. Attwood and Leslie Williams Professor of Law at Harvard Law School, where he directs the Center for Health Law Policy, Biotechnology, and Bioethics. A member of the National Academy of Medicine, his work focuses on the intersection of bioethics and the law. He has advised policymakers and global organizations on topics such as genetic privacy, medical AI, and reproductive rights, and his work has been featured by several prominent news outlets, including PBS, NPR, CNN, and The New York Times. View Fertility and Sterility at https://www.fertstert.org/
Implanon (etonogestrel implant) first received FDA approval in 2006, followed by the improved, radiopaque version, Nexplanon, approved by the FDA in 2010, which is now the only contraceptive implant available in the U.S. It was originally FDA approved for a 3-year use duration, although peer reviewed clinical data had demonstrated efficacy through year 5. Now, as of January 2026, the FDA has formally agreed to extend the label for 5-year use. In this episode, we will review the clinical data that prompted the FDA's decision, based on a multicenter, single-arm, open-label study evaluating contraceptive efficacy and safety during years 4 and 5 of implant use.1. https://www.contemporaryobgyn.net/view/fda-approves-5-year-use-for-etonogestrel-implant-68-mg-contraceptive2. Organon announces US Food and Drug Administration approval of supplemental new drug application extending duration of use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque. Organon. Press release. January 16, 2026. Accessed January 19, 2026. https://www.organon.com/news/organon-announces-us-food-and-drug-administration-approval-of-supplemental-new-drug-application-extending-duration-of-use-of-nexplanon-etonogestrel-implant-68-mg-radiopaque/3. Ali M, Akin A, Bahamondes L, et al. Extended Use Up to 5 Years of the Etonogestrel-Releasing Subdermal Contraceptive Implant: Comparison to Levonorgestrel-Releasing Subdermal Implant. Human Reproduction. 2016. 4. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device: 2 Years Beyond Food and Drug Administration-Approved Duration. American Journal of Obstetrics and Gynecology. 2017. 5. McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device Beyond the U.S. Food and Drug Administration-Approved Duration. Obstetrics and Gynecology. 2015.
In this encore episode, we detail connections between H. pylori and hypochlorhydria, while highlighting possible downstream effects on nutrient absorption. We examine how reduced gastric acidity can impair the liberation and assimilation of certain micronutrients, including iron, calcium, vitamin B12, and more; and we further discuss the impact of low stomach acid upon downstream digestive enzyme activation and gut microbial balance. Topics:1. Hypochlorhydria - Low stomach acid.2. H. pylori 3. Gastric Anatomy & Layers- The stomach: hollow, muscular organ for mechanical and chemical digestion.- Regions: Cardia, fundus, body, and pylorus.- Layers: Mucosa, Submucosa, Muscularis externa, Serosa4. Mucosal Layer - Surface mucous cells secrete a thick bicarbonate-rich, protective mucus.- Gastric pits lead to gastric glands, which contain specialized secretory cells.5. Specialized Gastric Cells- Parietal Cells: Secrete hydrochloric acid (HCl) and intrinsic factor (IF).- Chief Cells: Secrete pepsinogen (converted to pepsin by HCl) and gastric lipase.- Role of HCl: Activates pepsin, denatures proteins, and contributes to nutrient absorption.- Intrinsic factor and vitamin B12 absorption.6. Vitamin B12 Absorption- Essential for DNA synthesis, RBC formation, neurological function.- Released from food proteins by gastric acid and pepsin.- Impaired absorption.7. Role of Gastric Acid in Broader Micronutrient Absorption- Absorption of minerals.- Soluble, ionized state.- Iron: HCl aids in preventing insoluble precipitates and supports iron absorption.8. Protective Role of Gastric Acid- Acts as a line of defense against ingested pathogens.- Maintains low microbial diversity in the stomach.- Low HCl and Small Intestinal Bacterial Overgrowth.9. Symptoms of Low Stomach Acid- Bloating, early satiety, excessive belching.- Undigested food in stool, chronic constipation.- May reflect impaired enzymatic activation and digestive insufficiency.10. Conclusion- Multifactorial causes and downstream effects.- Optimal range, neither high nor low.Thank you to our episode sponsor: 1. "Longevity" with Protein, Probiotics, Bovine Colostrum, Collagen, and More. Use code CHLOE for 25% off.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.Thanks for tuning in!Follow Chloe on Instagram @synthesisofwellnessVisit synthesisofwellness.com
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Managing Editor Bridget Silverman and Editor-in-Chief Nielsen Hobbs consider the US Food and Drug Administration's average speed of a novel drug application review in 2025 (:34), including the loss of so-called “fast approvals” (5:33) and how reviewers managed to ignore the distractions caused by the changes (7:35). They also consider whether the layoffs and other departures will impact the review system in 2026 (11:16). More On These Topics From The Pink Sheet Average Metrics In A Turbulent Year: US FDA's 2025 Median Review Times Match PDUFA Goals: https://insights.citeline.com/pink-sheet/pink-sheet-perspectives/average-metrics-in-a-turbulent-year-us-fdas-2025-median-review-times-match-pdufa-goals-FOEPKT27UFAHPDS36HKJFOHOQE/ It's About Time: US FDA's Review Speed For Novel Approvals In 2025: https://insights.citeline.com/pink-sheet/pink-sheet-perspectives/its-about-time-us-fdas-review-speed-for-novel-approvals-in-2025-6LMDCANRRZGWTIDSRKFVXCJRPY/ US FDA's 2025 Staffing Turmoil Will Create 2026 Application Review Challenges: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-2025-staffing-turmoil-will-create-2026-application-review-challenges-AJIE7WRQ2ZFS7IOR5PA3OWFE2M/
Hey friend — I know life (and the news) can feel overwhelming, so this episode brings you back to basics: belly breathing to calm your nervous system and simple habits to protect your gut. Have you ever noticed that even when you eat “the right foods,” your digestion and symptoms still feel off? Stress and gut health are deeply connected, especially for those living with Hashimoto's. Understanding the link between stress and leaky gut patterns can help explain why flares happen even when your diet looks good on paper. In this episode, you'll learn: How chronic stress shifts your body out of “rest and digest” and disrupts digestion Why rushed eating and poor chewing can worsen gut permeability How stress-driven changes in the gut lining can contribute to autoimmune flares in Hashimoto's If you're feeling overwhelmed, tired of fighting your body, or stuck in a cycle of symptoms, this conversation will help you understand what's happening beneath the surface and why calming your stress response is a foundational step. SCHEDULE A COACHING SESSION: Hashimoto's Health Session https://healthwithhashimotos.com/book-now/ Listen to the ABIDE episode: https://healthwithhashimotos.com/150-hhl-abide/ And get 30 days free: https://abide.com/ref/hashimotospodcast JOIN THE HEALTH WITH HASHIMOTO'S COMMUNITY Unlock your wellness journey with the free Health with Hashimoto's community! Join a supportive community that's here for you every step of the way. The Health with Hashimoto's community is on Skool: https://www.skool.com/health-with-hashimotos/about Find all links on my resource page: https://healthwithhashimotos.com/resources/ ABOUT THE PODCAST & ESTHER: The Health with Hashimoto's podcast will help you explore the root causes of your autoimmune condition and discover holistic solutions to address your Hashimoto's thyroiditis. It is hosted by Esther Yunkin, a registered nurse, holistic health educator, and Hashimoto's warrior. This podcast is for informational and educational purposes. Please discuss any questions or concerns with your healthcare professional. These statements have not been evaluated by the Food and Drug Administration. Products mentioned are not intended to diagnose, treat, cure or prevent any disease.
In this episode of The Produce Moms Podcast, host Lori Taylor welcomes Kyle Diamantas, J.D., Deputy Commissioner for Human Foods at the Food and Drug Administration, for an in-depth conversation on food safety, regulatory leadership, and the future of the U.S. food system.
Leveling Up: Creating Everything From Nothing with Natalie Jill
What if the hormone replacement therapy you're taking is recycling in your body and creating the exact problems you're trying to solve? Most doctors test your hormone levels and prescribe accordingly. But here's what they're missing: it's not just about the hormones you make or the hormones you take – it's about how your unique body packages them, processes them, and eliminates them. And when this goes wrong, you can experience fibroids, unexplained weight gain, crushing fatigue, and worsening symptoms even though your blood tests look "normal." Dr. Betty Murray holds a PhD in hormone metabolism research and has spent over 20 years individualizing hormone therapy for women. In this conversation, we dive deep into the science that most practitioners completely miss: the three pathways your body uses to process estrogen, why your DNA matters (but isn't destiny), and how supporting detoxification in the wrong order can actually make things worse. This isn't a basic "should I do HRT" conversation. This is the advanced science that explains why some women thrive on hormone therapy while others struggle and what you can do about it if you're in the second group. We explore the difference between blood tests, urine tests, and Dutch tests (and why your doctor might be dismissing the most important one). Dr. Murray explains why taking supplements like DIM without understanding your complete pathway picture could be sabotaging your results. And she shares the critical downstream steps that must be supported first (sulfation and methylation) before anything else will work. If you've ever felt gaslit by "normal" lab results while feeling anything but normal, this episode is for you. Dr. Murray gives you permission to become your own health detective and shows you exactly where to start looking for answers. Listen now to discover the hormone processing pathways your doctor probably isn't testing, and why that might be the missing piece in your health journey. This is Part One of a two-part series. Part Two coming soon. Catch the full episode on YOUTUBE HERE: https://bit.ly/MidlifeConversationsYouTube Learn More About Dr. Betty Murray Instagram ➜ https://www.instagram.com/drbettymurray Website ➜ https://gethormonesnow.com/nataliejill Thank you to our show sponsors! BIOPTIMIZERS: Get the digestive enzymes I take with every meal here https://www.bioptimizers.com/nataliejill Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit For advertising inquiries: https://www.category3.ca/ Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen. Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.
A grounded Q&A episode focused on what actually keeps you consistent when motivation fades. Episode #241
In an industry known for pushing the bounds of human innovation, tech elites are now trying to push the bounds of their own bodies. The hot new biohacking trend is injectable peptides — similar to the ones found in GLP-1 medications like Ozempic. But these are not approved by the Food and Drug Administration.These gray-market peptides, largely from Chinese manufacturers, are being used by tech workers and founders. Not just to lose weight, but to optimize their health and performance in all manner of ways. “Marketplace Tech” host Meghan McCarty Carino speaks with independent journalist Jasmine Sun, who recently wrote about this for the New York Times.
In an industry known for pushing the bounds of human innovation, tech elites are now trying to push the bounds of their own bodies. The hot new biohacking trend is injectable peptides — similar to the ones found in GLP-1 medications like Ozempic. But these are not approved by the Food and Drug Administration.These gray-market peptides, largely from Chinese manufacturers, are being used by tech workers and founders. Not just to lose weight, but to optimize their health and performance in all manner of ways. “Marketplace Tech” host Meghan McCarty Carino speaks with independent journalist Jasmine Sun, who recently wrote about this for the New York Times.
I was blown away by today's guest in his ability to educate on complex mechanisms of actions, as well as his innovation and humility. We touched on so many topics that I had to split this episode in two parts! It was truly reassuring and empowering to learn about healing with natural, science-backed tools to reduce inflammation, the hidden root cause of aging, chronic disease, and cancer. In these two episodes, you will learn how inflammation impacts health at a cellular level and how you can take proactive steps to restore vitality, strengthen immunity, and age with resilience. Samuel Shepherd is an award winning physicist, inventor, and engineer with 42 patents and over 50 years of breakthroughs across biochemical, environmental, and medical engineering. His career has taken him from developing technologies for NASA and the Beijing Olympics to pioneering solutions in alternative energy and environmental remediation. But it was a deeply personal health challenge that led him to his most life-changing discovery. In 2003, Samuel was diagnosed with a rare, untreatable bone marrow cancer. Conventional medicine offered no viable path forward, so he turned to his lifelong expertise in science and innovation. After years of research, he developed ValAsta, the only patented glycosidic form of astaxanthin designed specifically to target inflammation, the root cause of most chronic disease. His unique delivery system makes astaxanthin far more bioavailable than typical supplements, producing remarkable results for energy, mobility, sleep, and overall vitality in both people and pets. Today, Samuel is on a mission to educate others about how inflammation accelerates disease and diminishes quality of life, and how targeted natural solutions can restore health. Beyond his formidable credentials, his personal story of overcoming terminal illness fuels his passion for helping others age with strength, energy, and resilience. Connect with Samuel via: Email: info@valasta.net Website: ValAsta FB: ValAsta Youtube: @ValAsta Visit https://marinabuksov.com for more holistic content. Music from https://www.purple-planet.com. Disclaimer: Statements herein have not been evaluated by the Food and Drug Administration. Products listed are not intended to diagnose, treat, cure, or prevent any diseases.
Hey Mama, Living in a fallen world means we will encounter circumstances and situations beyond our control. We will make mistakes and fall short, because we are human, and, inevitably, we will feel stress and anxiousness because we cannot control our husband, our children, or the events for the day. What we can control, however, is how we respond to these things. We can better respond to the stress of life by preparing our bodies, our hearts and our minds to receive and manage stress. Join me today as I share with you how I studied scripture during one of the most overwhelming times of my life, and learn how you, too, can study scripture to prepare your heart and mind to receive and manage stress in just three easy steps. For His Glory, Christen I would love to hear from you! >>Leave a Review >>Connect with me: Sign Up for Manage In The Moment Coaching Call: https://bit.ly/ManageStressInTheMoment Email me : naturalwellnessforbusymoms@gmail.com Sign Up to Become an Insider: https://bit.ly/naturalwellnessinsider Join Our FREE Facebook Community:https://www.facebook.com/groups/1789472588229094 >>Find Related Products Here: https://bit.ly/m/Natural-Wellness-for-Busy-Moms >> These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. >>I make a small commission when using the links above to purchase items.
It regulates 20 percent of the U.S. economy, and its commissioner has an aggressive agenda — faster drug approvals, healthier food, cures for diabetes and cancer. How much can he deliver? (Part two of “The Freakonomics Radio Guide to Getting Better.”) SOURCES:Marty Makary, commissioner of the Food and Drug Administration. RESOURCES:"Clinical Trials Affected by Research Grant Terminations at the National Institutes of Health," by Vishal Patel, Michael Liu, and Anupam Jena (JAMA Internal Medicine, 2025)."What the evidence tells us about Tylenol, leucovorin, and autism," by Matthew Herper (STAT, 2025)."I Run the F.D.A. Pharma Ads Are Hurting Americans." by Marty Makary (New York Times, 2025).Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health, by Marty Makary (2024). EXTRAS:"Are You Really Allergic to Penicillin?" by Freakonomics Radio (2025)."How to Fix the Hot Mess of U.S. Healthcare," by Freakonomics Radio (2021)."Bad Medicine, Part 3: Death by Diagnosis," by Freakonomics Radio (2016). Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Leveling Up: Creating Everything From Nothing with Natalie Jill
You're spending hundreds of dollars every month on high-quality supplements…so why do you still feel exhausted, inflamed, and stuck? The problem isn't the supplements you're buying. It's that your body might only be absorbing 10-15% of what you're taking. The rest? Literally flushed down the toilet. In this game-changing conversation with integrative health practitioner Lindsey Burwell, we uncover the absorption crisis affecting midlife women, and why your expensive supplement routine isn't delivering the results you're paying for. After years of bioanalytics testing, Lindsey discovered a shocking pattern: women faithfully taking their vitamins were showing up severely deficient in those exact same nutrients on lab work. We dive into what's really blocking absorption: your stagnant liver and inflamed gut, and why the toxic load of midlife has created a perfect storm where oral supplements simply can't get through. Lindsey explains the "first pass effect," why your liver prioritizes detoxification over vitamin absorption, and how the accumulation of stress, toxins, and hormonal changes has fundamentally changed how your body processes nutrients. But this isn't just a problem - Lindsey introduces a solution that bypasses the entire absorption crisis: transdermal vitamin delivery through patches that go directly into your bloodstream, completely avoiding the liver-gut bottleneck that's blocking your oral supplements. If you're tired of spending money on supplements that aren't working, feeling like you're doing everything right but getting nowhere, and wondering why your body has stopped responding like it used to, this episode will change everything. It's time to understand the absorption crisis in midlife and actually get the nutrients your body desperately needs. Catch the full episode on YOUTUBE HERE: https://bit.ly/MidlifeConversationsYouTube Learn More About Lindsey Burwell Instagram ➜ https://www.instagram.com/the.patchmethod Website ➜ https://www.thepatchmethod.com (use code NATALIEJILL for 20% off) Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit For advertising inquiries: https://www.category3.ca/ Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen. Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.
The Food and Drug Administration should “immediately” restore in-person dispensing requirements for the abortion pill, Sen. Bill Cassidy, R-La., told The Daily Signal. The senator cited safety concerns in pressing the administration to act. “You don't have to have a review to know that if a woman has an ectopic pregnancy, she's gonna have a […]
The Food and Drug Administration should “immediately” restore in-person dispensing requirements for the abortion pill, Sen. Bill Cassidy, R-La., told The Daily Signal. The senator cited safety concerns in pressing the administration to act. “You don't have to have a review to know that if a woman has an ectopic pregnancy, she's gonna have a problem,” Cassidy said. “You don't have to have a review to know that there's documented cases of people coerced into taking this.” Under President Joe Biden in April 2021, the administration stopped requiring that abortion drugs be dispensed to women in person. The Senate Health, Education, Labor, and Pensions Committee, of which Cassidy is the chair, is holding a hearing Wednesday on protecting women from abortion drugs. Cassidy hopes the hearing will “rehumanize” the issue by demonstrating how the pill harms both women and unborn children. Learn more about your ad choices. Visit megaphone.fm/adchoices
We all want to stay sharp, and forestall the cognitive effects of aging. But do brain supplements actually work? Are they safe? And why doesn't the F.D.A. even know what's in them? (Part one of “The Freakonomics Radio Guide to Getting Better.”) SOURCES:Marty Makary, commissioner of the Food and Drug Administration.Peter Attia, physician, author, and host of The Peter Attia Drive.Pieter Cohen, associate professor of medicine at Harvard Medical School, physician at the Cambridge Health Alliance. RESOURCES:"Protein Powders and Shakes Contain High Levels of Lead," by Paris Martineau (Consumer Reports, 2025)."Accuracy of Labeling of Galantamine Generic Drugs and Dietary Supplements," by Pieter Cohen, Bram Jacobs, Koenraad Van Hoorde, and Céline Vanhee (JAMA, 2024).Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health, by Marty Makary (2024).Outlive: The Science and Art of Longevity, by Petter Attia (2023)."Revealing the hidden dangers of dietary supplements," by Jennifer Couzin-Frankel (Science, 2015). EXTRAS:"China Is Run by Engineers. America Is Run by Lawyers." by Freakonomics Radio (2025)."How to Fix the Hot Mess of U.S. Healthcare," by Freakonomics Radio (2021). Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
© 2020-2026 Ivy Podcast Discovery LLC
